Ludger Ständker

This study identifies human histone H1.2 peptide as an antimicrobial agent against Pseudomonas aeruginosa, showing dose- and pH-dependent growth inhibition without cytotoxicity to mammalian cells.

The paper identifies Laudanosine as an inhibitor of TPC2-dependent viral entry, effective against Ebola and related viruses without cytotoxicity.

This study identifies the Man-PTS as a receptor for Angicin in streptococci and defines structural features associated with its antimicrobial activity.

This study evaluates the antimicrobial peptide C14R against ESKAPE pathogens, showing potent bactericidal activity and biofilm inhibition.

This paper identifies Trypstatin, a Kunitz-type protease inhibitor that inhibits TMPRSS2 and related proteases, showing broad-spectrum antiviral activity against SARS-CoV-2, influenza, and other respiratory viruses.

This study identifies Retinol Binding Protein 4 (RBP4) as a natural activator of latent HIV-1 through JAK/STAT5 and JNK pathways, offering a new strategy for reactivating viral reservoirs.

This paper optimizes a HIV-1 entry inhibitor peptide using ReaxFF molecular dynamics simulations, reducing its size while maintaining or improving antiviral activity.

The paper investigates how EPI-X4 binds to CXCR4 using simulations and experiments, leading to the design of more potent and safer CXCR4 antagonists.